Though still a highly speculative equity, Stereotaxis (NASDAQ:STXS) appears to be in a sweet spot for potential revenue growth and for becoming an acquisition target by larger companies that are in the fields of medical devices and/or robotics. Shares of STXS have had a volatile last several months, but have recently performed well and appear poised to continue doing so throughout 2014. See a recent performance chart (click to enlarge):
Stereotaxis is the market leader in robotic navigation solutions for the treatment of arrhythmias and coronary disease, with a portfolio of over 100 patents for use in hospital surgical suites. The company's key device uses magnets to generate a Tesla field in a patient's heart, and then uses...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|